Screening, Early Detection of T2DM and Management of Prediabetes

Accredited by

Activity Description

Presentations
Audiovisual tutorial on key topics that review evidence-based data, information, and resources essential for clinical decision making in the management of patients with type 2 diabetes. These presentations include a faculty-moderated question and answer session. Learn about new developments in the screening, diagnosis, and management of patients with prediabetes, early diabetes, and advanced diabetes, as well as patients with diabetes and common comorbidities.

Virtual Patients
Challenging case studies simulating real visits from patients with prediabetes and established type 2 diabetes. These visits will review key steps in clinical decision making and approaches for overcoming barriers to optimal patient outcomes.

Newsletters
These practice-based newsletters will provide management pearls and practical strategies for improving patient outcomes.

Statement of Educational Need

Type 2 diabetes mellitus (T2DM) is a major source of morbidity and mortality for millions of people throughout the world. Patients with T2DM are at risk for macrovascular complications, including coronary artery disease, stroke, and peripheral artery disease, as well as microvascular complications such as neuropathy, nephropathy, and retinopathy. Genetic susceptibility and phenotypic characteristics like obesity, lifestyle, and cultural factors impact an individual's risk of developing T2DM. People with impaired glucose tolerance or impaired fasting glucose are at high risk for progression to T2DM. These individuals with so-called prediabetes are typically asymptomatic and, therefore, may not be identified for many years. Targeted screening is recommended to identify those at high risk for T2DM in order to initiate early treatment. Lifestyle interventions aimed at weight reduction, healthy diet, and increased physical activity can prevent or delay the development of diabetes and its complications.

Goals of Program

The Virtual Diabetes Institute was created to provide the latest information, clinical resources, practice tools, and educational opportunities for healthcare providers committed to improving the health and lives of people with type 2 diabetes.

Learning Objectives

• Identify risk factors for type 2 diabetes and related cardiovascular complications
• Screen at-risk patients for type 2 diabetes according to recommended guidelines and using appropriate testing methods
• Develop and implement evidence-based treatment strategies for patients with prediabetes

Target Audience

These activities have been designed to meet the educational needs of primary care physicians and other health care professionals who are involved in the management of patients with type 2 diabetes.

Requirements for Successful Completion

A passing grade of 60% is required before credit can be obtained. Once you have completed the posttest, please visit your “Office” in the Virtual Diabetes Institute to obtain your certificate.

Disclosure and Resolution of Conflicts of Interest

SciMed requires all individuals who are involved with the development or delivery of content in any of its activities to disclose financial relationships they may have with commercial interests. Should SciMed determine that any of the disclosed relationships constitutes a conflict of interest, as defined by the ACCME, SciMed will act to resolve such a conflict.

When asked to report relevant financial relationships with commercial interests, faculty reported the following:

Lawrence Blonde, MD

Consultant
Amylin Pharmaceuticals, Inc.; AstraZeneca US; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Daiichi Sankyo Co., LTD.; GlaxoSmithKline plc; Halozyme; Johnson & Johnson Services Inc; Mannkind Corporation; Merck & Co., Inc; Novo Nordisk Inc; Orexigen Therapeutics, Inc; Roche; Sanofi-Aventis U.S. LLC; Santarus, Inc; VeroScience, LLC.

Investigator
Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company; Johnson & Johnson Services Inc; Novo Nordisk Inc; Roche; Sanofi-Aventis U.S. LLC.

Speaker's Bureau
AstraZeneca US; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Daiichi Sankyo Co., LTD.; Merck & Co., Inc; Novo Nordisk Inc; Santarus, Inc; VeroScience, LLC.

Other
Dr Blonde's late spouse's estate contains shares of Amylin Pharmaceuticals, Inc and Pfizer, Inc.

Edward Horton, MD

Consultant
Amylin Pharmaceuticals, Inc; Eli Lilly and Company; Merck & Co., Inc; Roche; Gilead; Medtronic, Inc.

Grant/Research Support
Amylin Pharmaceuticals, Inc; Eli Lilly and Company.

Chair/Member of Data Safety Monitoring Boards for studies sponsored by these companies: Boehringer Ingelheim Pharmaceuticals; ChemoCentryx, Inc; GI Dynamics; MacroGenics, Inc; Takeda Pharmaceuticals North American, Inc; Theracos, Inc.

Frank Lavernia, MD

Speaker's Bureau
Abbott Laboratories.

The materials for this activity were peer reviewed by Scott Yager, MD, Private Practice, East Brunswick, NJ. Dr Yager has no relevant financial relationships to report.

The following planners and managers reported having a relevant financial relationship with a commercial interest:
Shari Fallet, DO - Pfizer (owns stock)

All other SciMed personnel involved in the development of content for this activity have no relevant financial relationships to report.

Accreditation Statement

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Statement of Commercial Support

Sponsored by  

Supported by an independent education grant from

Designation of Credit

SciMed designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclaimer

This CME online material is designed for use by health care professionals for educational purposes only. Information and opinions offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.

Although SciMed makes every effort to ensure accurate information, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

Disclosure of Unlabeled Use

The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of SciMed or the commercial supporter. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentions.

Contact Information for Questions about the Activity

Ryan Raffel
Program Director
SciMed, LLC
rraffel@scimedny.com

Hardware / Software Requirements

For Windows

Windows 2000, XP or higher
Adobe Acrobat Reader 6 or higher
1024 x 768 displays

For Macintosh

OS X 10.3 or higher
Adobe Acrobat Reader 6 or higher
1024 x 768

Browser requirements for Windows:

IE 6.0 and above
Firefox 2.x and above

Browser requirements for Macintosh:

Safari 2.x and above Firefox 2.x and above

Other:

Flash Player 9.0
Connection speed minimum: Cable, DSL or equivalent

Instructions for Receiving Credit

To obtain your CME Credit, please visit your Office in the Virtual Diabetes Institute or go to www.VirtualDiabetesInstitute.org